Treatment of hallucinosis/psychosis in Parkinson's disease by an investigational drug

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jun 2015 Pooled analysis of two extension trials (ACP103-010, ACP103-015) for long-term efficacy: results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
16 Jun 2015 According to an Acadia Pharmaceuticals media release, data from this study were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
01 Mar 2010 Efficacy results published in Neuropsychopharmacology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com